Michiko Mori's research while affiliated with Tokyo Women's Medical University and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (3)
Several observational studies have shown that estrogen replacement therapy decreases cardiovascular mortality and morbidity in postmenopausal women. However, The Women's Health Initiative (WHI) study has found that women receiving estrogen plus progestin had a significantly higher risk of breast cancer, coronary heart disease, stroke, and pulmonary...
Several observational studies have shown that estrogen replacement therapy decreases cardiovascular mortality and morbidity in postmenopausal women. However, The Women's Health Initiative (WHI) study has found that women receiving estrogen plus progestin had a significantly higher risk of breast cancer, coronary heart disease, stroke, and pulmonary...
To study maternal lipoprotein(a) levels in normal pregnancy and in pregnancy with evidence of vascular disease in the maternal uteroplacental circulation defined by Doppler ultrasound study.
Maternal venous blood was collected from 75 normal pregnant women and 68 pregnant women with evidence of potential uteroplacental vascular disease identified b...
Citations
... In addition to the release of vasorelaxants, estrogens also prevent the activation of endothelium, which constitutes an essential component of endothelial dysfunction. Both E 2 and its metabolites such as estron and 17-epiestriol, as well as 5a-androstane-3a,17b-diol-(3adiol) and 5a-androstane-3b,17b-diol-(3b-diol), two dihydrotestosterone metabolites that are unable to bind the androgen receptor but exhibit affinity for ERs, blunt the cell-surface expression of vascular cell adhesion molecule-1 (VCAM1), intercellular cell adhesion molecule (ICAM-1), E-selectin, P-selectin, as well as CD40 and CD40L in endothelial cell exposed to proatherogenic factors such as TNFa, IL1B, lipopolysaccharide (LPS), IFNg or lysophosphatidylcholine (LPC; Nathan et al. 1999, Simoncini et al. 1999, Mukherjee et al. 2002, Mori et al. 2004, Geraldes et al. 2006, Ling et al. 2006, Norata et al. 2010, Thor et al. 2010, Rauschemberger et al. 2011. At the same time, E 2 reduces the monocyte expression of a 4 b 1 and a L b 2 integrins, binding partners for VCAM1 and ICAM-1, respectively, in a process involving downregulation of RAC1 activity (Friedrich et al. 2006). ...
... 26 On the other hand, Parvin and Mori et al pointed out an association between elevated levels of Lp(a) and preeclampsia. 27,28 Satter and Baksu et al showed no statistically significant differences between normotensive pregnant, and preeclamptic women, with respect to plasma Lp(a) levels. 26,29 Harpel et al 30 revealed that Hcy, even at a low concentration of 8 µmol/L, could modify the structure of Lp(a) by exposing lysine-binding domains in the apo(a) molecule. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/11431281089784906-1665714339358_Q64/Hiroaki-Ohta-4.jpg)
... Third, it has been reported that mice display sex differences in the cardiac inflammation response to injury, which are ostensibly caused by sex hormones. [57][58][59] For our study, to avoid potential confounds related to the effects of sex hormones on monocytes from male and female mice, we restricted our study to the use of male mice. Nevertheless, the routine treatment for breast cancer in women always includes doxorubicin, and so the effects of this compound in females is important. ...
